How Pharmaceutical Companies Can Enter the TDDS Field

Transdermal drug delivery systems represent a commercially mature but technically demanding category of pharmaceutical manufacturing. For companies whose current portfolio is concentrated in oral solid dosage forms — tablets, capsules, granules — the path into TDDS looks unfamiliar. The formulation science is different. The equipment is different. The regulatory package is different. And the clinical value proposition, when executed correctly, is genuinely compelling.

This article addresses the practical question: what does it actually take for a pharmaceutical manufacturer to enter the TDDS space, and what are the realistic entry points?

If you are evaluating production equipment as part of this assessment, Huanghai's pharmaceutical film manufacturing platforms — including the MJ150 coating machine — support continuous wet-coating processes for pharmaceutical-grade transdermal patch production.

Why TDDS Is Worth Evaluating Now

The commercial case for TDDS has been established for decades, with approved products in pain management, smoking cessation, hormone replacement, and central nervous system indications. What has changed more recently is the breadth of companies for whom TDDS entry has become strategically relevant.

Several factors make TDDS worth evaluating today:

First-pass metabolism avoidance. For APIs where oral bioavailability is limited by hepatic first-pass effects, the transdermal route can deliver meaningful improvements in dose efficiency. This is not a new insight — it is the clinical rationale behind some of the earliest TDDS approvals — but it remains a valid reason to evaluate reformulation when oral dosage forms are underperforming or when generic competition on oral products has eroded margins.

Sustained release with improved compliance. Chronic therapy patients — whether managing pain, cardiovascular conditions, or CNS disorders — benefit from dosing regimens that do not require multiple daily administrations. A once-daily or 3-day patch represents a qualitatively different adherence proposition than a thrice-daily oral tablet. For pharmaceutical companies developing therapies for chronic indications, TDDS deserves a place in the formulation strategy conversation.

Competitive differentiation. In markets crowded with tablet and capsule generics, a novel TDDS formulation of an established API can represent genuine clinical differentiation — different dosing frequency, different patient experience, potentially different regulatory exclusivity periods. This is not universally applicable, but it is a legitimate business consideration for life cycle management strategies.

Growing interest in non-oral, non-injectable formats. Across pharmaceutical markets, demand for patient-friendly administration formats continues to increase. TDDS sits in a category — non-invasive, depot-type — that aligns with this trend without the cold chain and injection site considerations of biologics.

Who Should Seriously Consider TDDS Entry

Not every pharmaceutical company is a good fit for TDDS. The following profiles suggest meaningful strategic alignment:

Manufacturers with existing ODF capability. Companies already running continuous wet-coating platforms for oral dissolving film are the closest to TDDS from a process infrastructure standpoint. The core equipment logic is the same — coating, drying, converting — and the knowledge base transfers significantly. In some cases, the same physical platform (with changeover) can support both ODF and TDDS production.

Companies with APIs well-suited to transdermal delivery. The pharmacokinetic fit between the API and the transdermal route is the primary technical filter. APIs that are potent (low therapeutic dose), lipophilic, and stable are generally better TDDS candidates. If your portfolio includes such compounds currently administered orally, the transdermal route is worth a feasibility assessment.

Manufacturers targeting regulated export markets. TDDS products with robust regulatory dossiers command higher value in export markets than commodity oral generics. For manufacturers looking to move up the value chain in markets like the US, EU, or Southeast Asia, TDDS is a viable differentiation strategy.

Health supplement or functional ingredient companies. The concept of transdermal delivery for nutraceuticals and cosmeceuticals is commercially active, though the regulatory and efficacy evidence base is less mature than for pharmaceutical TDDS. Companies in this space exploring skin-applied functional ingredient delivery should understand the distinction between pharmaceutical TDDS and cosmetic patch products before investing in production capacity.

The Entry Path: From Formulation to Commercial Scale

TDDS entry follows a recognizable sequence, regardless of company size:

Phase 1: Feasibility Assessment

Before any equipment purchase, the core question is: does your API actually work via the transdermal route?

This requires: - Pharmacokinetic modeling to assess whether target plasma levels are achievable through skin permeation - In vitro permeation studies using Franz cell diffusion apparatus (a standard tool for initial TDDS evaluation) - Initial formulation screening — which polymer system, which adhesive, which permeation enhancers, if any, are needed?

This phase is typically conducted at lab scale, using small-format coating equipment and standard analytical tools. It does not require commercial-scale production infrastructure.

Huanghai collaborates with the National Institute of Pharmaceutical Engineering in China — one of the country's leading teams for transdermal drug delivery formulation research. Clients who need formulation development support concurrent with equipment evaluation can engage this partnership as part of a comprehensive entry approach.

Phase 2: Pilot-Scale Process Validation

Once a formulation direction is identified, process validation at pilot scale is the next step. This means: - Coating trials on a lab-scale machine to establish coating weight targets, drying parameters, and web handling protocols - Initial content uniformity and in vitro drug release assessments - Stability samples under ICH conditions - Process documentation sufficient to support subsequent scale-up

Huanghai's MJ150-L lab-scale coating machine operates at 8,000–10,000 films/hour and uses the same process logic as the commercial MJ150 platform. This is a significant advantage: formulation and process parameters developed on the MJ150-L translate directly to the commercial platform, avoiding the costly revalidation burden that often occurs when lab equipment and production equipment use different process architectures.

Phase 3: Commercial-Scale Production

Commercial-scale TDDS production on a continuous wet-coating platform involves: - Coating machine (MJ150: 20,000 films/hour capacity) - Patented hot-air drying tunnel (CN201668734U) — progressive temperature profiling, uniform airflow, 20–30% higher drying efficiency compared to plate-based competitors - Backing liner lamination - Cutting and packaging — MJF180 automatic system for high-speed automated conversion - GMP documentation and batch release infrastructure

The MJ150 platform supports both ODF and TDDS production — the core wet-coating and drying process is the same. Switching between formats requires format-specific tooling changes with Huanghai engineering support; in practice, most customers operate separate dedicated lines for ODF and TDDS. For companies interested in dual-format capability on a single platform, contact Huanghai to evaluate the configuration for your specific product requirements.

Regulatory Considerations: What to Expect

TDDS regulatory strategy is more complex than for oral generics, but the pathway is well-defined in major markets:

US (FDA): TDDS products are regulated as drug products under the NDA/ANDA framework. In vitro/in vivo correlation (IVIVC) and bioequivalence studies specific to transdermal products are required. FDA has published specific guidance on bioequivalence approaches for topical and transdermal products.

EU (EMA): Similar to the US framework; biosimilar and generic TDDS products follow the ANDA-equivalent pathway. EMA has published guidance on quality aspects of transdermal patches, including adhesive performance standards.

China and other markets: The specific registration pathway depends on product attributes, active ingredients, intended claims, and local regulatory classification. Manufacturers should confirm requirements based on their target market regulations.

A critical point for manufacturing companies entering TDDS: the regulatory dossier for a TDDS product is more demanding than for most oral generics. Content uniformity, IVRT, adhesive performance testing, and long-term stability including skin adhesion performance all require dedicated analytical methods and validation. Building this capability — whether in-house or through CRO partnerships — is part of the realistic entry investment.

Frequently Asked Questions

Q: How do we know if our API is a realistic TDDS candidate? A: The primary filters are: (1) potency — the API should achieve therapeutic plasma levels at a skin application area of 5–50 cm², which means low doses are easier to achieve transdermally; (2) lipophilicity — log P between approximately 1–3 is generally favorable for passive skin permeation; (3) molecular weight — generally below 500 Da for passive permeation without enhancement strategies; (4) no severe skin sensitization at the required dose. A preliminary Franz cell permeation study using excised skin models is the standard first technical assessment. This is work done at lab scale, not on production equipment.

Q: Can our existing ODF wet-coating line be used to start TDDS development? A: If your ODF line uses continuous wet-coating and drying, it is likely process-compatible with pharmaceutical TDDS formulation work. The primary equipment differences between ODF and TDDS arise in post-coating conversion — ODF requires slitting and cutting; TDDS requires backing liner lamination and die-cutting. If your ODF line is a Huanghai MJ150 platform, the core process is compatible with TDDS formulation work — however, switching between ODF and TDDS formats requires format-specific tooling changes with Huanghai engineering support. Contact Huanghai to evaluate the specific configuration for your product.

Q: What is the typical investment range for a pilot-scale TDDS entry program? A: This depends heavily on whether formulation development is conducted in-house or through a CRO, and whether new equipment is purchased or existing platforms are adapted. As a framework: pilot-scale formulation and process development typically precedes commercial equipment specification. Huanghai's MJ150-L is the appropriate pilot-scale platform and allows direct scale-up to the MJ150 commercial system. Equipment investment decisions should be discussed based on your specific production targets, product design, and market timelines.

Q: How long does it typically take to go from initial TDDS feasibility to commercial launch? A: For a pharmaceutical drug product, the development timeline from initial formulation work to commercial approval is typically 4–7 years in major regulated markets, depending on the API, market, and regulatory pathway (NDA vs ANDA vs generic). Process equipment can be specified and installed in parallel with clinical development once the formulation direction is established — and in many cases, equipment procurement begins after pilot-scale data are generated. This parallel track is how manufacturers avoid equipment lead times becoming the rate-limiting step at the back end of development.

Q: What formulation types are best for a first TDDS product? A: For companies entering TDDS without deep transdermal formulation experience, solvent-based matrix systems with established PSA adhesives represent the most tractable starting point. The formulation science is well-documented, the manufacturing process is straightforward on a wet-coating line, and the regulatory precedent is extensive. Aqueous systems and hydrogel systems are viable alternatives but may require additional formulation development investment.

Conclusion

Entering the TDDS field is not a trivial undertaking, but it is a well-defined one. The technology is mature, the regulatory frameworks are established, and the commercial rationale — for the right APIs and the right companies — is genuine. The most common mistakes companies make are either starting too late (underestimating the development timeline) or starting with the wrong equipment platform (misaligning formulation type with process technology).

For pharmaceutical manufacturers evaluating TDDS entry, Huanghai offers continuous wet-coating platforms from lab scale through commercial production, plus access to formulation development partnership through our collaboration with the National Institute of Pharmaceutical Engineering.

Contact Huanghai to discuss your API profile, development timeline, and equipment requirements for pharmaceutical TDDS entry.

To learn more about Huanghai's complete TDDS production solution, visit the TDDS Complete Solution page.

For details on our IQ/OQ/PQ certification suite and FDA compliance credentials, see our Certifications & Compliance page.